Table 3.
Prevalence odds ratios of reporting select contraceptive methods as safea for women with specific characteristics or medical conditions during Phase 2 (after guidance) compared with Phase 1 (before guidance).
| USMEC characteristic or medical condition | USMEC classification | aPRc (95% CI) |
|---|---|---|
| IUDs for adolescents | 1 or 2b (Safe) | 1.26 (1.14, 1.39) |
| IUDs for immediately postpartum women (<10 min after delivery of placenta) | 1 or 2b (Safe) | 1.55 (1.28, 1.88) |
| IUDs for postpartum women (10 min after delivery of placenta to <4 weeks postpartum) | 2 (Safe) | 1.39 (1.20, 1.61) |
| IUDs for nulliparous women | 2 (Safe) | 1.20 (1.14, 1.27) |
| IUDs for women with uterine fibroids | 2 (Safe) | 1.17 (1.07, 1.28) |
| IUDs for women with HIV | 2 (Safe) | 1.37 (1.21, 1.54) |
| DMPA for adolescents | 1 or 2b (Safe) | 1.04 (1.01, 1.08) |
| DMPA for breastfeeding women<1 month postpartum | 2 (Safe) | 1.12 (1.05, 1.19) |
| DMPA for breastfeeding women ≥1 month postpartum | 1 (Safe) | 1.06 (1.01, 1.10) |
| DMPA for women with obesity (BMI ≥30 kg/m2) | 1 or 2b (Safe) | 1.17 (1.09, 1.25) |
| DMPA for women with history of bariatric surgery | 1 (Safe) | 1.17 (1.09, 1.26) |
| DMPA for women with IBD | 2 (Safe) | 1.22 (1.13, 1.31) |
| COCs for breastfeeding women ≥1 month postpartum without other risk factors for VTE | 2 (Safe) | 1.07 (0.99, 1.17) |
| COCs for women with obesity (BMI ≥30 kg/m2) | 2 (Safe) | 1.05 (0.95, 1.16) |
| COCs for smokers aged ≥35 years | 3 or 4b (Unsafe) | 0.92 (0.56, 1.53) |
| COCs for women with a history of bariatric surgery via malabsorptive procedures | 3 (Unsafe) | 0.84 (0.73, 0.96) |
aPR, adjusted prevalence ratio; BMI, body mass index; CI, confidence interval; COCs, combined oral contraception; DMPA, depot medroxyprogesterone acetate; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IUD, intrauterine device; USMEC=United States Medical Eligibility Criteria for Contraceptive Use; VTE, venous thrombosis.
For analyses, we grouped USMEC classifications 1 and 2 to represent “safe” and USMEC classifications 3 and 4 to represent “unsafe”. As defined, USMEC 1, a condition for which there is no restriction for the use of the contraceptive method; USMEC 2, a condition for which the advantages of using the contraceptive method generally outweigh the theoretical or proven risks; USMEC 3, a condition for which the theoretical or proven risks usually outweigh the advantages of using the method; USMEC 4, a condition that represents an unacceptable health risk if the method is used.
Depending on the level of the condition. For more detail, see https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1.htm?s_cid=rr6503a1_w.
Phase 2 versus Phase 1, adjusted for provider type, training in IUD insertion, time since completion of formal clinical training, number of female patients of reproductive age seen per week, and proportion of female patients of reproductive age who are adolescents.